Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ILP100-Topical in Diabetic Foot Ulcers
NCT05608187Phase 2Terminated
- Sponsor
- Ilya Pharma
- Start
- Sep 2022
- Primary completion
- Dec 2024
- Modality
- Gene Editing, Gene Silencing, Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of emilimogene sigulactibac in diabetic foot ulcer (DFU), sponsored by Ilya Pharma. Started Sep 2022; status: terminated.
02
Drugs
emilimogene sigulactibac
03
Conditions
diabetic foot ulcer (DFU)
Beyond the preview
Go deeper on NCT05608187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05608187.